0.35
+0.0283(+8.84%)
Currency In USD
| Previous Close | 0.32 |
| Open | 0.51 |
| Day High | 0.53 |
| Day Low | 0.33 |
| 52-Week High | 3.33 |
| 52-Week Low | 0.31 |
| Volume | 194.69M |
| Average Volume | 123,070 |
| Market Cap | 12.64M |
| PE | -1.34 |
| EPS | -0.26 |
| Moving Average 50 Days | 0.38 |
| Moving Average 200 Days | 0.96 |
| Change | 0.03 |
Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026
GlobeNewswire Inc.
Mar 02, 2026 1:00 PM GMT
Advancing FDA-Cleared Phase IIa Parkinson’s Program Targeting Neuroinflammation Dual-Path Strategy Combines Clinical Development with Revenue-Generating Nugevia™ JUPITER, FL, March 02, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: J
Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago
GlobeNewswire Inc.
Feb 25, 2026 1:30 PM GMT
Jupiter Neurosciences, Inc. Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago JUPITER, FL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "
Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution
GlobeNewswire Inc.
Feb 23, 2026 2:30 PM GMT
Repayment Commencement Deferred to April 1, 2026 Core Economic Terms of $6.0 Million Financing Remain Unchanged JUPITER, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company focus